Le Lézard
Classified in: Health
Subjects: NPT, STP, AVO

NAPHS Statement on White House Opioid Commission's Final Report


WASHINGTON, Nov. 2, 2017 /PRNewswire-USNewswire/ -- The following is a statement from Mark Covall, President and CEO, National Association of Psychiatric Health Systems: 

The National Association of Psychiatric Health Systems (NAPHS) applauds the President's Commission on Combating Drug Addiction and the Opioid Crisis for starting to address America's deadly opioid crisis.

We are especially pleased to see the commission has reiterated its earlier recommendation to remove the Medicaid Institutions for Mental Diseases (IMD) exclusion in one of several policy changes that the panel suggested in its final report on Nov. 1.

In October, NAPHS released Blueprint for Recovery: Increasing Access to Inpatient and Residential Behavioral Health, a white paper that outlines practical steps federal officials can take to address this public health emergency. We will continue to work with the administration, Members of Congress and other relevant stakeholders to implement effective policy changes that will ensure access to mental health and substance use disorder services for all who need it.

The National Association of Psychiatric Health Systems advocates for behavioral health and represents provider systems that are committed to the delivery of responsive, accountable, and clinically effective prevention, treatment, and care for children, adolescents, adults, and older adults with mental and substance use disorders. Its members are behavioral healthcare provider organizations that own or manage more than 800 specialty psychiatric hospitals, general hospital psychiatric and addiction treatment units and behavioral healthcare divisions, residential treatment facilities, youth services organizations, and extensive outpatient networks. The association was founded in 1933.

SOURCE National Association of Psychiatric Health Systems (NAPHS)


These press releases may also interest you

at 07:15
Edwards Lifesciences plans to announce its operating results for the quarter ended March 31, 2024 after the market closes on Thursday, April 25, 2024, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To...

at 07:15
Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system...

at 07:15
NeoGenomics, Inc. , a leading oncology testing services company, today announced two promotions within its senior leadership team, effective immediately. Warren Stone has been promoted to Chief Commercial Officer and will lead NeoGenomics' clinical...

at 07:13
Calliditas Therapeutics AB ("Calliditas"), today announced additional data analyses from the 2-year Phase 3 NeflgArd trial evaluating Nefecon (TARPEYO® (budesonide) delayed-release capsules/Kinpeygo®) in patients with IgA nephropathy (IgAN), were...

at 07:13
In a significant leap towards combating health inequities and improving community health, HDR Healthcare Network is proud to implement the HealthPrevent360 program, a comprehensive healthcare solution designed to transform the landscape of preventive...

at 07:05
Aldeyra Therapeutics, Inc. (Aldeyra), a clinical-stage biotechnology company developing innovative therapies for the treatment of immune-mediated and metabolic diseases, today announced that the company will host a Research & Development Day from...



News published on and distributed by: